Ventricular tachycardia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 10: Line 10:


The implantation of an [[ICD]] is more effective than drug therapy for prevention of sudden cardiac death due to [[VT]] and [[VF]], but may be constrained by cost issues, and well as patient co-morbidities and patient preference.
The implantation of an [[ICD]] is more effective than drug therapy for prevention of sudden cardiac death due to [[VT]] and [[VF]], but may be constrained by cost issues, and well as patient co-morbidities and patient preference.
===Trials on Beta-Blockers on Mortality in Patients With Heart Disease and Complex Ventricular Arrhythmias===


[[Category : Electrophysiology]]
[[Category : Electrophysiology]]

Revision as of 16:35, 31 October 2011

Ventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ventricular Tachycardia from other Disorders

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

Cardiac MRI

Other Diagnostic Tests

Treatment

Medical Therapy

Electrical Cardioversion

Ablation

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ventricular tachycardia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ventricular tachycardia medical therapy

CDC onVentricular tachycardia medical therapy

Ventricular tachycardia medical therapy in the news

Blogs on Ventricular tachycardia medical therapy

to Hospitals Treating Ventricular tachycardia medical therapy

Risk calculators and risk factors for Ventricular tachycardia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Avirup Guha, M.B.B.S.[3]

Antiarrhythmic drug therapy

Drugs such as amiodarone, epinephrine and vasopressin may be used in addition to defibrillation to terminate VT while the underlying cause of the VT can be determined. Possible causes or contributing factors to VT can be remembered as the six H's and five T's: Hypovolemia, Hypoxia, Hydrogen ion (acidosis), Hypo- or Hyperglycemia, Hypothermia; and Toxins, Tamponade (cardiac), Tension pneumothorax, Thrombosis, Trauma.

Long term anti-arrhythmic therapy may be indicated to prevent recurrence of VT. Beta-blockers and a number of class III anti-arrhythmics are commonly used.

For some of the rare congenital syndromes of VT, other drugs, and sometimes even catheter ablation therapy may be useful.

The implantation of an ICD is more effective than drug therapy for prevention of sudden cardiac death due to VT and VF, but may be constrained by cost issues, and well as patient co-morbidities and patient preference.

Trials on Beta-Blockers on Mortality in Patients With Heart Disease and Complex Ventricular Arrhythmias

Template:WS Template:WH